Preclinical studies targeting single members of the lysyl oxidase family (LOX and LOXL2) using antibody-based approaches have previously shown efficacy in in vivo models of cancer16,19, whereas others have shown negative outcomes47, suggesting both pro- and anti-tumorigenic roles for individual lysyl oxidase family member activity at different stages of tumor progression and metastasis (Extended Data Fig. 7c). This evidence concerns the gene LOX and neoplasm.